
|Articles|October 15, 2006
New Products & Services
Irvine, CA-The Cryocare CN2 System from Endocare, Inc. has received 510K clearance from the FDA. The device uses the freezing capability of nitrogen at the point between gas and liquid-"critical nitrogen"-to destroy cancerous tissue quicker and more cost-effectively than argon can, according to the manufacturer. The speed and precision of this new technology can expedite procedures, Endocare says, because it is easy to use and it delivers a colder, more powerful ice ball at the end of the probes.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Dosing begins in trial of alpha radioligand therapy for mCRPC
2
Novel tool may help predict early PSA response to ARPIs in mHSPC
3
Fed Ghali, MD, highlights trial of consolidative local therapy following EV/P
4
RCMIGI trial supports feasibility of reduced margins in image-guided prostate radiotherapy
5




















